131碘治疗和加用地塞米松治疗Graves病的短期临床观察

目的探讨131碘治疗和加用地塞米松治疗Graves病的临床疗效。方法将符合入选条件的98例Graves病患者随机分成研究组和对照组。从临床症状和体征、甲状腺功能(TT3、TT4、TSH)、临床控制率、基础代谢率等方面观察地塞米松配合131碘对Graves病的治疗效果。进行自身前后对照和组间两两比较。结果治疗后1周,研究组患者TT3水平较治疗前明显下降(P<0.01),TT4较治疗前有明显下降(P<0.01),基础代谢率较治疗前有明显下降(P<0.01),两组患者治疗前后血清TT3、TT4及基础代谢率差值比较差异有统计学意义(P<0.01)。结论地塞米松加131碘治疗Graves病疗效满意,能较快的改善自觉症状,减少早期并发症,预防Graves病危象发生。

Short term therapy observation on hyperthyroidism patients received 131I and glucocorticoid following therapy

Objective To investigate the clinical outcomes in patients treated with glucocorticoid following 131I therapy,and to evaluate its clinical values.Methods A total of 98 subjects were selected and classified into dexamethasone following 131I therapy group(study group,n=49) and only 131I therapy group(control group,n=49).The theraputic outcomes of glucocorticoid following 131I therapy were evaluated by clinical symptoms,signs,thyroid function(TT3,TT4,TSH),clinical control rate and basal metabolic rate.Results In study group,serum TT3,TT4 levels and basal metabolic rates were significantly decreased after treatment compared to the levels of pre-treatment(P<0.01),in control group,serum TT3 was significantly increased(P<0.05),TT4 levels and basal metabolic rates were also significantly increased(P<0.01).There were statictical differences in serum TT3,TT4 levels and basal metabolic rates between study group and control group after treatment(P<0.01).Conclusion Dexamethasone administration following 131I therapy is the preferred treatment for patients with Graves disease.Dexamethasone combination therapy can effectively control the symptoms,prevent early complication of 131I therapy,and prevent the crisis of Graves disease.